Ownership Capital B.V. Sells 9,508 Shares of Insulet Co. (NASDAQ:PODD)

Ownership Capital B.V. cut its stake in shares of Insulet Co. (NASDAQ:PODD) by 3.3% during the 4th quarter, HoldingsChannel reports. The firm owned 277,624 shares of the medical instruments supplier’s stock after selling 9,508 shares during the period. Insulet comprises 1.3% of Ownership Capital B.V.’s investment portfolio, making the stock its 21st largest position. Ownership Capital B.V.’s holdings in Insulet were worth $60,239,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. C WorldWide Group Holding A S grew its holdings in shares of Insulet by 42.4% during the 4th quarter. C WorldWide Group Holding A S now owns 167,908 shares of the medical instruments supplier’s stock valued at $36,433,000 after purchasing an additional 50,000 shares during the last quarter. Alliance Wealth Advisors LLC UT grew its holdings in shares of Insulet by 31.4% during the 4th quarter. Alliance Wealth Advisors LLC UT now owns 2,128 shares of the medical instruments supplier’s stock valued at $462,000 after purchasing an additional 509 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Insulet during the 4th quarter valued at approximately $86,000. Truist Financial Corp grew its holdings in shares of Insulet by 154.3% during the 4th quarter. Truist Financial Corp now owns 4,651 shares of the medical instruments supplier’s stock valued at $1,009,000 after purchasing an additional 2,822 shares during the last quarter. Finally, Syon Capital LLC acquired a new stake in Insulet during the 4th quarter worth approximately $288,000.

Analysts Set New Price Targets

Several equities research analysts recently commented on PODD shares. Barclays cut their target price on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Piper Sandler cut their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Stifel Nicolaus lifted their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $243.21.

Insulet Stock Up 1.2 %

Shares of Insulet stock traded up $2.02 during trading on Friday, reaching $166.19. 636,152 shares of the company traded hands, compared to its average volume of 670,432. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $335.91. The company has a 50 day moving average price of $171.51 and a 200-day moving average price of $179.39. The firm has a market capitalization of $11.64 billion, a PE ratio of 57.11, a P/E/G ratio of 2.96 and a beta of 0.98.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same quarter in the previous year, the company earned $0.55 EPS. Insulet’s quarterly revenue was up 37.9% compared to the same quarter last year. As a group, equities research analysts expect that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.90% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.